These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 36332985)
21. Superficial neurofibroma: a lesion with unique MRI characteristics in patients with neurofibromatosis type 1. Lim R; Jaramillo D; Poussaint TY; Chang Y; Korf B AJR Am J Roentgenol; 2005 Mar; 184(3):962-8. PubMed ID: 15728625 [TBL] [Abstract][Full Text] [Related]
22. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Nguyen R; Dombi E; Widemann BC; Solomon J; Fuensterer C; Kluwe L; Friedman JM; Mautner VF Orphanet J Rare Dis; 2012 Oct; 7():75. PubMed ID: 23035791 [TBL] [Abstract][Full Text] [Related]
23. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study. Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430 [TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009 [TBL] [Abstract][Full Text] [Related]
25. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015 [TBL] [Abstract][Full Text] [Related]
26. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Gross AM; Singh G; Akshintala S; Baldwin A; Dombi E; Ukwuani S; Goodwin A; Liewehr DJ; Steinberg SM; Widemann BC Neuro Oncol; 2018 Nov; 20(12):1643-1651. PubMed ID: 29718344 [TBL] [Abstract][Full Text] [Related]
27. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768 [TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514 [TBL] [Abstract][Full Text] [Related]
29. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Waggoner DJ; Towbin J; Gottesman G; Gutmann DH Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438 [TBL] [Abstract][Full Text] [Related]
30. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Mautner VF; Asuagbor FA; Dombi E; Fünsterer C; Kluwe L; Wenzel R; Widemann BC; Friedman JM Neuro Oncol; 2008 Aug; 10(4):593-8. PubMed ID: 18559970 [TBL] [Abstract][Full Text] [Related]
31. C2 neurofibromas in neurofibromatosis type 1: genetic and imaging characteristics. Waqar M; Huson S; Evans DG; Ealing J; Karabatsou K; George KJ; Soh C J Neurosurg Spine; 2019 Jan; 30(1):126-132. PubMed ID: 30485203 [TBL] [Abstract][Full Text] [Related]
32. Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas. Karmazyn B; Cohen MD; Jennings SG; Robertson KA Pediatr Radiol; 2012 Oct; 42(10):1218-22. PubMed ID: 22722872 [TBL] [Abstract][Full Text] [Related]
33. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822 [TBL] [Abstract][Full Text] [Related]
34. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report. Sassi I; Bouida MA; Hasnaoui A; Zemni I; Ben Dhieb T J Med Case Rep; 2024 Jan; 18(1):15. PubMed ID: 38216958 [TBL] [Abstract][Full Text] [Related]
35. Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1. Toledano H; Dotan G; Friedland R; Cohen R; Yassur I; Toledano-Alhadef H; Constantini S; Rootman MS Childs Nerv Syst; 2021 Jun; 37(6):1909-1915. PubMed ID: 33751171 [TBL] [Abstract][Full Text] [Related]
36. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Dombi E; Solomon J; Gillespie AJ; Fox E; Balis FM; Patronas N; Korf BR; Babovic-Vuksanovic D; Packer RJ; Belasco J; Goldman S; Jakacki R; Kieran M; Steinberg SM; Widemann BC Neurology; 2007 Feb; 68(9):643-7. PubMed ID: 17215493 [TBL] [Abstract][Full Text] [Related]
37. Selumetinib in Children with Inoperable Plexiform Neurofibromas. Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457 [TBL] [Abstract][Full Text] [Related]
38. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051 [TBL] [Abstract][Full Text] [Related]
39. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623 [TBL] [Abstract][Full Text] [Related]
40. Analysis of orbital plain radiographs for orbital deformities in neurofibromatosis type 1 patients, with special reference to alterations of the orbital rim as indicators of adjacent plexiform neurofibroma. Friedrich RE; Rother J; Christ G; Lehmann M; Eulenburg CG; Giese M; Scheuer HA Anticancer Res; 2013 Mar; 33(3):1081-90. PubMed ID: 23482785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]